{"brief_title": "A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.", "brief_summary": "The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.", "condition": ["Breast Cancer"], "intervention_type": ["Drug"], "intervention_name": ["ABT-751"], "criteria": "Inclusion Criteria - Stage IIIB or IV breast cancer. - Recurrent tumor after or while on taxane therapy (taxol or taxotere). - Able to tolerate normal activities of daily living. - Adequate bone marrow, kidney and liver function. Exclusion Criteria - Pregnant or breast feeding. - No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Breast Neoplasms", "Taxane"], "id": "NCT00063102"}